Fluticasone/salmeterol: labeling change.
The fixed-dose combination of fluticasone and salmeterol has no place in the treatment of asthma or chronic obstructive pulmonary disease (COPD).
D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013256:Steroids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000730:Androstadienes; D001993:Bronchodilator Agents; D013256:Steroids; D000420:Albuterol